Assess use of rimegepant and other medications for acute treatment of migraine, as well as frequency of moderate or severe migraine days on scheduled and nonscheduled rimegepant dosing days.

This 52-week open-label extension phase of a 12-week, phase 2/3, randomized, double-blind, placebo-controlled study of rimegepant for the preventive treatment of migraine (NCT03732638) included adults aged ≥18 years with a history of 4-18 moderate to severe monthly migraine attacks. Subjects completing 12 weeks of double-blind treatment with rimegepant 75 mg or placebo every other day (QOD) could continue with open-label rimegepant 75 mg scheduled QOD for preventive treatment of migraine over 52 weeks. On nonscheduled rimegepant dosing days, subjects could take rimegepant 75 mg up to once per day as needed for acute treatment. Subjects received 30 rimegepant tablets per month. Subjects could also use other medications for the acute treatment of migraine on scheduled and nonscheduled dosing days if needed. Months were defined as 4-week intervals.

Through 52 weeks, subjects used rimegepant a mean (SD) of 14.2 (1.90) days per month. On scheduled and nonscheduled rimegepant dosing days over 52 weeks, mean (SD) moderate or severe migraine days per month were 1.4 (1.71) and 1.4 (1.63), respectively, and mean (SD) other acute migraine medication days per month were 0.6 (1.09) and 0.6 (1.08), respectively. On nonscheduled rimegepant dosing days, subjects used rimegepant as an acute migraine medication a mean (SD) of 1.1 (1.53) days per month and rimegepant plus other acute migraine medication 0.2 (0.59) days per month.